This is a clip from our event with BioIDEA: Biotech vs COVID-19. Our CEO, Andrew Satz, explains how our technology works, with specific attention to our work on COVID-19. Give it a listen below (transcription beneath video).
We use nearly a hundred billion data points across a wide range of biological data. That includes gene sequences, biological structures, biophysical properties and more. And we integrate all that data and then apply our evolutionary algorithms and computational tests. This all gives our artificial intelligence engine the ability to make statistically informed decisions.
To be clear, this process is not about replacing the work of scientists in the lab. Instead, it’s about accelerating and augmenting the decision-making being made by life scientists as they work on drugs for the coronavirus.
We’re driven, at our company, to use computational technology to support each key member in the drug discovery and development process, in order to prevent failure in the lab, in animal tests, or in clinical trials.
Today, our technology works by taking an existing antibody sequence. For example, an antibody that targets the spike of the coronavirus that may have come from an animal or a patient that recovered from the coronavirus. We then apply our proprietary evolutionary algorithms to generate evolutionary mutated daughters of those antibodies. By taking those antibodies that we know target the coronavirus and applying our algorithms, we can generate variants that could be used in larger segments of the population.